Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 503

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Direct Effects of Type I Interferons on Cells of the Immune System

Hervas-Stubbs, Sandra, Perez-Gracia, Jose Luis, Rouzaut, Ana, Sanmamed, Miguel F., Le Bon, Agnes, Melero, Ignacio·2011·Clinical Cancer Research

Abstract

Type I interferons (IFN-I) are well-known inducers of tumor cell apoptosis and antiangiogenesis via signaling through a common receptor interferon alpha receptor (IFNAR). IFNAR induces the Janus activated kinase–signal transducer and activation of transcription (JAK-STAT) pathway in most cells, along with other biochemical pathways that may differentially operate, depending on the responding cell subset, and jointly control a large collection of genes. IFNs-I were found to systemically activate natural killer (NK) cell activity. Recently, mouse experiments have shown that IFNs-I directly activate other cells of the immune system, such as antigen-presenting dendritic cells (DC) and CD4 and CD8 T cells. Signaling through the IFNAR in T cells is critical for the acquisition of effector functions. Cross-talk between IFNAR and the pathways turned on by other surface lymphocyte receptors has been described. Importantly, IFNs-I also increase antigen presentation of the tumor cells to be recognized by T lymphocytes. These IFN-driven immunostimulatory pathways offer opportunities to devise combinatorial immunotherapy strategies. Clin Cancer Res; 17(9); 2619–27. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-1114

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 90 references

Research works printed but not linked: 5

  1. Ortaldo, 1980, Effects of metabolic inhibitors on spontaneous and interferon-boosted human natural killer cell activity, J Immunol, 125, 1839, 10.4049/jimmunol.125.4.1839 · doi:10.4049/jimmunol.125.4.1839
  2. Wedemeyer, 2002, Polyethylene glycol-interferon: current status in hepatitis C virus therapy, J Gastroenterol Hepatol, 17, S344, 10.1046/j.1440-1746.17.s3.26.x · doi:10.1046/j.1440-1746.17.s3.26.x
  3. Pizzocaro, 2001, Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study, J Clin Oncol, 19, 425, 10.1200/JCO.2001.19.2.425 · doi:10.1200/jco.2001.19.2.425
  4. Kiladjian, 2006, High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a, Blood, 108, 2037, 10.1182/blood-2006-03-009860 · doi:10.1182/blood-2006-03-009860
  5. Vanni, 2006, Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives, Cancer Treat Rev, 32, 445, 10.1016/j.ctrv.2006.06.001 · doi:10.1016/j.ctrv.2006.06.001

Cited by

See all 503

Metadata

Authors
Hervas-Stubbs, S., Perez-Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Le Bon, A., & Melero, I.
Venue
Clinical Cancer Research
Published
2011-05-01
Volume
17
Issue
9
Pages
2619-2627
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2091018161
Cited by
503
References
90
FWCI
11.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Direct Effects of Type I Interferons on Cells of the Immune System. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-1114
The paper
Hervas-Stubbs, S., Perez-Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Le Bon, A., & Melero, I. (2011). Direct Effects of Type I Interferons on Cells of the Immune System. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-1114

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.